D-Lysergic acid ethylamide (LAE-32) is a derivative of ergine.[1][2] It is reported to have some LSD-like effects but is weaker and shorter lasting, with an active dose reported to be between 0.5 and 1.5 milligrams.
Clinical data | |
---|---|
Other names | LAE; Lysergic acid ethylamide; d-Lysergic acid ethylamide; d-Ethyllysergamide, |
Routes of administration | Oral |
Pharmacokinetic data | |
Metabolism | Hepatic |
Excretion | Renal |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C18H21N3O |
Molar mass | 295.386 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(verify) |
It was studied by the CIA as part of Project MKULTRA. Documents published by the CIA under the Freedom of Information Act suggest it causes "a schizophrenia-like condition" but it allows people with schizophrenia to remain indifferent to their disorder.